BioSpace News Archive

Passage Bio, Inc., a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, announced that management will participate in two upcoming virtual investor conferences in March.

Clearside Biomedical, Inc. announced that it will participate in the following investor conferences in March 2022.

First Wave BioPharma, Inc., announced that Sarah Romano has joined the Company as its Chief Financial Officer effective immediately.

Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today announced that Alexander Duncan, Ph.D., Chief Scientific Officer of Walden Biosciences, will lead a seminar and participate in a panel discussion at the 4th Annual Chronic Kidney Disease Drug Development (previously CKD3) Summit taking place March 1-3, 2022, in Boston.

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today confirmed the TULSA-PRO® system’s new compatibility with GE Healthcare’s 3T Magnetic Resonance Imaging (“MRI”) scanners.

Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company focused on developing treatments for central nervous system (CNS) movement disorders and fluency disorders, today announced that it has entered into a license agreement with East Carolina University.

Milestone Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, announced that members of management will present at the following investor conferences.

Amniocentesis is a prenatal test also known as amniotic fluid test or AFT. It is carried out to diagnose the chromosomal abnormalities and fetal infections.

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio announced the availability of the Lumipulse G pTau 181 Plasma assay for the fully automated LUMIPULSE G immunoassay systems.

International medical imaging IT and cybersecurity company Sectra and AZ Sint-Maria Halle in Belgium have signed a contract for Sectra’s enterprise imaging solution.